# A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

> clinical trial · VERIFIED · 2026-07-23

Status: ACTIVE_NOT_RECRUITING · Sponsor: BeOne Medicines · Condition: Relapsed/Refractory Follicular Lymphoma

- Company: BeOne Medicines
- Sector: Relapsed/Refractory Follicular Lymphoma
- Primary source: https://clinicaltrials.gov/study/NCT05100862

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.